Status:
COMPLETED
Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents
Lead Sponsor:
Novartis Vaccines
Conditions:
Meningococcal Disease
Eligibility:
All Genders
11-18 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and immunogenicity of two serogroup B meningococcal vaccines in comparison to placebo administered to healthy adolescents ages 11 to 18 years.
Eligibility Criteria
Inclusion
- Healthy Adolescents between and including 11-18 years of age, who provide written informed consent.
Exclusion
- Previous or suspected disease caused by N. meningitidis; or previous immunization with a serogroup B meningococcal vaccine; Any acute, chronic or progressive disease.
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
203 Patients enrolled
Trial Details
Trial ID
NCT00297817
Start Date
February 1 2006
End Date
April 1 2007
Last Update
December 1 2016
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Encinitas, California, United States, 92024
2
Atlanta, Georgia, United States, 30322
3
St Louis, Missouri, United States, 63110
4
Cleveland, Ohio, United States, 44118